Drug Trial Radar · NCT04798469
Pain Alleviation With Testosterone in Opioid-Induced Hypogonadism
Last checked: Nov 20, 2026Latest source record: Jul 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
150
Planned (sponsor's estimate)
Start
Jan 10, 2022
Primary completion
Sep 30, 2027
Study completion Dec 30, 2027
Sponsor
- Lead sponsor
- Brigham and Women's HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Mar 15, 2021
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Male only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The aim of this trial is to evaluate whether testosterone replacement results in greater improvement in pain perception, pain tolerance, sexual function, fatigue, and quality of life when compared with placebo in men with chronic spinal pain treated with opioids who have opioid-induced hypogonadism (low testosterone).
Conditions
- Opioid Use
- Pain
- Hypogonadism, Male
Interventions
Testosterone Undecanoate 250 MG/MLDrug
Intramuscular administration at a dose of 750 mg at baseline, weeks 4, and week 14.
PlaceboDrug
Intramuscular administration of placebo at baseline, weeks 4, and week 14.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Changes in scores in the Pain Interference Subscale of the Brief Pain Inventory (BPI) questionnaireTime frame: Baseline, 3 months, and 6 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Brigham and Women's Hospital
Boston, Massachusetts · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.